Abiomed continues rebound, expects to file Impella PMA this fiscal year

Abiomed continues rebound, expects to file Impella PMA by end of fiscal year

Abiomed (NSDQ:ABMD) shares continued their rebound today from a plunge begun late last year after news broke of a federal investigation and new FDA requirements for its flagship Impella heart pump.

The Danvers, Mass.-based medical device company’s stock soared last week after it released its fiscal 4th-quarter and 2013 results, reporting soaring profits on solid, double-digit sales growth. Shares continued the trend today, rising about 1.5% in mid-morning trading.

In December, an FDA advisory panel recommended that some categories of heart pumps, including the Impella, be required to submit pre-market approval applications to the agency even if they’ve already been approved via the FDA’s 510(k) clearance protocol, continuing the slide for ABMD shares begun when it revealed a federal probe into its marketing of the Impella device.

Last week, chairman, president & CEO Michael Minogue told analysts during a conference call that the company expects to complete its PMA submission to the FDA by the end of fiscal 2014. The federal watchdog agency is allowing Abiomed to submit the PMA in 3 separate modules, Minogue said, consisting of preclinical testing data; manufacturing and quality systems data; and clinical data and conclusions. It’s still unclear whether the agency will ask its Circulatory Devices advisory panel to review Abiomed’s PMA before a final decision is reached, he said.

"The PMA that Abiomed intends to submit to the agency will contain all reasonably known information which includes extensive real world experience and readily available medical device reporting or MDR safety records," Minogue said during the call. "The review clock starts when the final module is submitted and the expectation is for 180 days without a panel requirement and 320 days with it. Until this is completed, everything is business as usual for Abiomed and our Impella 510(k) clearances."

Minogue said early indications are that the PMA could be granted without Abiomed having to run another clinical trial, citing its trove of data covering real-world use of the Impella pump.

"The feedback at the December panel meeting from the physicians and also the FDA indicated there could be the potential of sufficient existing data to file for PMA without doing another trial, but again we may be asked to do additional work, which could be potentially the single-arm study, prospective study or just more additional registry work or post-market analysis," he said. "We are in discussions with the agency requiring these requirements."

"We’d like to be one of the first success stories in the industry that’s converted from a 510(k) through the 515 process to PMA," Minogue added. "We’re excited to kind of be the role model.

As for the federal subpoena that kicked off Abiomed’s woes last year, Minogue said the company is still working with the U.S. Attorney’s Office for the District of Columbia "to resolve the issue and cooperate."

"We are just going to follow their path and have confidence in our ability to work with them and to resolve it one way or the other," he said. "We do not have any other comments on that."

ABMD shares were trading at $20 even as of about 11:30 this morning, up 1.5% on the day.

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply